Eli Lilly and Company $LLY Shares Purchased by Assetmark Inc.

Assetmark Inc. boosted its holdings in Eli Lilly and Company (NYSE:LLY) by 16.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 52,218 shares of the company’s stock after acquiring an additional 7,240 shares during the quarter. Assetmark Inc.’s holdings in Eli Lilly and Company were worth $40,706,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Arkadios Wealth Advisors boosted its stake in Eli Lilly and Company by 43.2% during the 2nd quarter. Arkadios Wealth Advisors now owns 17,647 shares of the company’s stock valued at $13,756,000 after purchasing an additional 5,327 shares in the last quarter. Barnes Dennig Private Wealth Management LLC boosted its stake in Eli Lilly and Company by 46.8% during the 2nd quarter. Barnes Dennig Private Wealth Management LLC now owns 615 shares of the company’s stock valued at $479,000 after purchasing an additional 196 shares in the last quarter. World Investment Advisors boosted its stake in Eli Lilly and Company by 16.5% during the 2nd quarter. World Investment Advisors now owns 20,687 shares of the company’s stock valued at $16,126,000 after purchasing an additional 2,931 shares in the last quarter. Lathrop Investment Management Co. boosted its stake in Eli Lilly and Company by 7.0% during the 2nd quarter. Lathrop Investment Management Co. now owns 1,228 shares of the company’s stock valued at $957,000 after purchasing an additional 80 shares in the last quarter. Finally, Flagship Harbor Advisors LLC boosted its stake in Eli Lilly and Company by 0.6% during the 2nd quarter. Flagship Harbor Advisors LLC now owns 6,226 shares of the company’s stock valued at $4,853,000 after purchasing an additional 37 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $842.28 on Friday. The stock has a market cap of $797.18 billion, a PE ratio of 55.05, a price-to-earnings-growth ratio of 1.21 and a beta of 0.47. The business has a fifty day simple moving average of $777.69 and a 200-day simple moving average of $770.84. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $935.63.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping the consensus estimate of $6.42 by $0.60. The business had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company’s revenue was up 53.9% compared to the same quarter last year. During the same quarter last year, the firm posted $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be issued a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.7%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 39.22%.

Insider Buying and Selling at Eli Lilly and Company

In other news, CEO David A. Ricks acquired 1,632 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the acquisition, the chief executive officer owned 546,601 shares in the company, valued at approximately $352,431,926.77. The trade was a 0.30% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Gabrielle Sulzberger acquired 117 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average price of $641.18 per share, with a total value of $75,018.06. Following the completion of the acquisition, the director owned 2,703 shares of the company’s stock, valued at $1,733,109.54. This represents a 4.52% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders bought 4,514 shares of company stock valued at $2,894,841 in the last quarter. Corporate insiders own 0.13% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Wall Street Zen lowered Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 20th. BMO Capital Markets raised their price objective on Eli Lilly and Company from $840.00 to $930.00 and gave the stock an “outperform” rating in a research note on Monday, October 20th. Cantor Fitzgerald set a $925.00 price objective on Eli Lilly and Company and gave the stock an “overweight” rating in a research note on Thursday, October 9th. Guggenheim reissued a “buy” rating and set a $948.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, October 16th. Finally, DZ Bank raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $936.47.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.